CRISPR Therapeutics reports trial results for in vivo gene-editing therapy CTX310

A news report indicates CRISPR Therapeutics has reported trial results for CTX310, its in vivo CRISPR gene-editing therapy targeting ANGPTL3 for severe hypertriglyceridemia and refractory hypercholesterolemia. Efficacy and safety figures were not available in the feed summary and have not been verified from a primary source.